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Drug-induced phospholipidosis (PLD) is characterized by phos-
pholipid accumulation within the lysosomes of affected tissues, re-
sulting in lysosomal enlargement and laminar body inclusions. Nu-
merous adverse effects and toxicities have been linked to PLD-
inducing drugs, but it remains unknown whether drug-induced
PLD represents a distinct toxicity or cellular adaptation. In sil-
ico and immortalized cellular models have been used to evaluate
the PLD potential of new drugs, but these systems have some lim-
itations. The aims of this study were to determine whether pri-
mary sandwich-cultured hepatocytes (SCH) can serve as a sensi-
tive and selective model to evaluate hepatic drug-induced PLD,
and to evaluate the impact of PLD on the uptake and biliary ex-
cretion of probe substrates, taurocholate (TC) and rosuvastatin
(RSV). Rat SCH were cultured for 48 h with prototypic hepatic
PLD-inducing drugs, amiodarone (AMD), chloroquine (CHQ), de-
sipramine (DES), and azithromycin (AZI), as well as the renal
PLD inducer gentamicin (GTM). LysoTracker Red localization
and transmission electron microscopy indicated enlarged lysoso-
mal compartments and laminar body inclusions in SCH treated
with AMD, CHQ, DES, and AZI, but not GTM, relative to con-
trol. PLD resulted in a 51–92% decrease in the in vitro biliary
clearance of both TC and RSV; the biliary excretion index signifi-
cantly decreased for TC from 88 to 35–73%. These data suggested
that PLD significantly reduced both organic anion transporting
polypeptide-mediated uptake, and bile salt export pump-mediated
biliary transport processes. The current study demonstrates that
the rat SCH system is a promising model to study hepatic PLD in
vitro. Altered hepatic transport of anionic substrates secondary to
drug-induced PLD is a novel finding.
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Drug-induced phospholipidosis (PLD) manifests as lysoso-
mal accumulation of phospholipids, resulting in development of
concentric lamellar bodies visible via the gold standard method,
electron microscopy (Reasor et al., 1989). Predictive computer
models of PLD potential have suggested that most precipitant
drugs are weakly basic and have amphiphilic features. These
cationic amphiphilic drugs (CADs), including antiarrhythmics,
antidepressants, and anti-infectives, are able to cross the lyso-
somal membrane where they become protonated at low physi-
ologic pH (pH 3–5) and trapped due to an inability to exit the
lysosomal compartment following protonation. Lysosomal trap-
ping and PLD have been observed in many different tissue/cell
types including lung, nerve, kidney, and liver cells (Kaloyanides
and Pastoriza-Munoz, 1980; Logan et al., 2013; Ndolo et al.
2010; Oikawa et al., 2005; Reasor and Kacew, 1996; Ruben
et al., 1989; Shahane et al., 2013). Several mechanisms have
been proposed for CAD-induced PLD, including inhibition of
lysosomal phospholipases, inhibition of H+-ATPases and direct
binding to the phospholipids, resulting in inert phospholipid-
drug complexes (Joshi et al., 1989; Reasor et al., 2006).
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PLD has been associated with hepatic/alveolar fibrosis
(amiodarone; AMD), renal tubular toxicity (gentamicin; GTM),
and QT-wave prolongation secondary to inhibition of human
ether-à-go-go-related gene (hERG) channels in the heart (ta-
moxifen) (Agoston et al., 2003; Kaloyanides and Pastoriza-
Munoz, 1980; Oikawa et al., 2005; Sun et al., 2013; Xia et al.,
2011). Accordingly, significant industrial and regulatory atten-
tion, including the formation of the Food and Drug Administra-
tion sponsored PLD Working Group in 2004, has been devoted
to developing sensitive and specific models to detect PLD dur-
ing preclinical drug development. In response, multiple com-
puter, non-cell, and cell-based models have been evaluated.
Computer models utilizing molecular structure, as well as non-
cell-based and cell-based models focusing on altered gene ex-
pression or lysosomal uptake and retention of fluorescent probes
(e.g., Nile red, LysoTracker Red), have shown modest sensitiv-
ity and specificity (Atienzar et al., 2007; Kazmi et al., 2013;
Ndolo et al., 2010; Pelletier et al., 2007; Ploemen et al., 2004).
Unfortunately, computer or non-cell based models may not be
predictive of PLD induced by metabolites, and often fail to pre-
dict which tissue(s) will be affected due to the absence of rele-
vant metabolizing enzymes and transport processes. Methods to
visualize lysosomal compartments within the cell to screen for
PLD potential are of particular interest to reduce the burden of
confirmatory studies with electron microscopy.
Although most PLD-inducing drugs contain a cationic am-
phiphilic moiety, metabolically-deficient models may not accu-
rately predict PLD liability of metabolites. Sandwich-cultured
hepatocytes (SCH) are fully differentiated, express relevant me-
tabolizing enzymes and hepatic transporters, and can be used
to assess hepatic transport processes involved in the clearance
of endogenous and exogenous substrates (Chandra et al., 2001;
LeCluyse et al., 1996; Li, 1997; Liu et al., 1999; Swift et al.,
2010). Therefore, this established system was selected for sub-
sequent investigations to test the hypothesis that SCH represent
a sensitive and selective model to screen for drug-induced hep-
atic PLD. Lysosomal dysfunction secondary to PLD may al-
ter the cycling of transporters to and from the relevant mem-
branes (basolateral or canalicular), resulting in altered hepatic
transporter-mediated clearance of susceptible compounds.
The goal of the present study was to determine whether pri-
mary rat SCH can serve as a sensitive and selective model to
evaluate hepatic drug-induced PLD and determine if PLD al-
ters hepatic transport processes. Structurally diverse drugs that
cause PLD to varying degrees by distinct mechanisms were se-
lected for investigation. First, lysosomal localization was de-
termined using LysoTracker Red. Second, the presence or ab-
sence of PLD was confirmed using transmission electron mi-
croscopy. Third, hepatic uptake by sodium-taurocholate co-
transporting polypeptide (Ntcp) and organic anion transport-
ing polypeptides (Oatps), and biliary excretion by the bile salt
export pump (Bsep), multidrug resistance-associated protein 2
(Mrp2), and breast cancer resistance protein (Bcrp) were evalu-
ated using taurocholate (TC) and rosuvastatin (RSV) as probes
for Ntcp/Bsep and Oatps/Mrp2/Bcrp, respectively. Results
demonstrated that rat SCH are a promising screening tool for
drug-induced PLD.
MATERIALS AND METHODS
Chemicals and reagents. Dexamethasone, TC, AMD,
chloroquine (CHQ), desipramine (DES), azithromycin (AZI),
GTM, Hanks’ balanced salt solution (HBSS; standard buffer),
Ca2+/Mg2+-free HBSS (Ca2+-free buffer), and thiazolyl blue
tetrazolium bromide were purchased from Sigma-Aldrich
(St. Louis, MO). RSV was purchased from Toronto Research
Chemicals (Toronto, Ontario, Canada). [3H]TC (1 mCi/ml;
>97% purity) and [3H]RSV (1 mCi/ml; >97% purity) were
purchased from PerkinElmer (Waltham, MA) and Ameri-
can Radiolabeled Chemicals (St. Louis, MO), respectively.
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine
serum, penicillin/streptomycin and insulin were purchased
from Gibco (Grand Island, NY). Minimum essential medium,
nonessential amino acids, and LysoTracker Red were pur-
chased from Invitrogen (Carlsbad, CA). BioCoat culture
plates, BioCoat glass inserts, Matrigel extracellular matrix,
and insulin/transferrin/selenium culture supplement were
purchased from BD Biosciences (Bedford, MA). All other
chemicals and reagents were of analytical grade and readily
available from commercial sources.
Animals. Male Wistar wild-type (WT) rats (250–350 g) from
Charles River Labs (Wilmington, MA) were used as hepatocyte
donors. Rats were allowed free access to water and food and
were acclimated for a minimum of 1 week prior to experimen-
tation. All animal procedures complied with the guidelines of
the Institutional Animal Care and Use Committee at the Uni-
versity of North Carolina at Chapel Hill (Chapel Hill, NC). All
procedures were performed while rats were under full anesthe-
sia with ketamine/xylazine (140/8 mg/kg ip).
Culture of primary rat hepatocytes in sandwich configura-
tion. Primary rat hepatocytes were isolated and cultured as de-
scribed previously (Swift et al., 2010). Briefly, hepatocytes
were seeded at a density of 1.75 × 106 cells/well onto six-well
BioCoat plates. Approximately 24 h later, hepatocytes were
overlaid with 2 ml of 0.25 mg/ml BD Matrigel basement mem-
brane matrix in DMEM. Hepatocytes were cultured for 4 days
to allow formation of canalicular networks before experimenta-
tion; medium was changed daily. For single (‘acute’) admin-
istration experiments, the 2–4 day feeding medium was not
supplemented with DMSO or PLD-inducing drugs. For multi-
ple (‘chronic’) administration experiments, the feeding medium
used on days 2–4 (48 h) of culture was supplemented with
0.1% DMSO (vehicle control, used to solubilize PLD-inducing
drugs), AMD (1, 10, or 50M), CHQ (1 or 10M), DES (1,
10, or 50M), AZI (1, 10, or 50M), or GTM (1mM). The con-
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centrations of the PLD-inducing drugs selected for investigation
were based on in vivo plasma concentrations and estimated hep-
atic concentrations (Micromedex, 2014).
MTT assay. Following incubation of rat SCH with the PLD
inducers or vehicle control at 37◦C for 48 h, the medium was
aspirated, and 2 ml of 0.5 mg/ml thiazolyl blue tetrazolium bro-
mide solution in plain DMEM was added. After 30 min, the
medium was aspirated, and 1 ml of 0.04M HCl in isopropanol
was added to solubilize the cells. Lysates were analyzed by ab-
sorbance at 570 and 650 nm. SCH treated for 48 h with 100M
CHQ and 0.1% DMSO served as positive and negative/vehicle
controls, respectively.
LysoTracker Red localization in rat sandwich-cultured hep-
atocytes. On day 4, the medium from SCH treated with PLD-
inducing drugs or vehicle control was aspirated and replaced
with fresh medium containing 100nM LysoTracker Red. After
30 min at 37◦C, wells were washed rapidly twice with warm
Dulbecco’s phosphate buffered saline, and both light and fluo-
rescent (excitation/emission wavelengths of 577/590 nm) digi-
tal images were captured using a Zeiss Axiovert 200TV (Thorn-
wood, NY) inverted phase contrast microscope. Images were
analyzed using ImageJ software (free online at rsbweb.nih.gov).
Electron microscopy of rat sandwich-cultured hepatocytes.
BioCoat glass inserts were placed in the BioCoat plates, and
hepatocytes were cultured as described above. The medium was
aspirated on day 4, and then SCH were fixed for 1 h with 2 ml
of 2.5% glutaraldehyde/1% tannic acid in 0.1M sodium cacody-
late (pH 7.3). The fixation solution was aspirated, and SCH were
washed with 0.1M cacodylate solution three times for 5 min
each. SCH were postfixed with 1% osmium tetroxide in 0.1M
cacodylate for 20 min, then rinsed three times with distilled wa-
ter and two times with 50% ethanol for 5 min each. SCH were
stained further with 2% uranyl acetate in 50% ethanol for 30
min. Finally, the SCH were dehydrated with increasing concen-
trations of ethanol (two times with 70, 80, 90, and 95%, and
then three times with 100%, for 5 min each), infiltrated with
propylene oxide (1:1, 2:1, and 3:1 ratios of Epon 812 [Hatfield,
PA] to propylene oxide for 1 h each), and finished with pure
Epon for 1 h. The glass inserts were removed from the BioCoat
plates, embedded in Epon 812, and allowed to cure at 60◦C for
at least 18 h. The glass inserts were dissolved with concentrated
hydrofluoric acid and thinly sectioned on a Leica Ultracut ultra-
microtome (Leica Microsystems, Buffalo Grove, IL). Sections
were placed on copper grids and restained with uranyl acetate
and lead citrate, after which digital images were captured us-
ing a Tecnai 12 electron microscope (Hillsboro, OR). Multiple
SCH sections from each treatment were imaged using a Gatan
Multiscan digital camera (Pleasanton, CA).
Probe substrate transport in rat sandwich-cultured hepato-
cytes. Determination of the uptake and biliary excretion of the
probe substrates TC (Ntcp/Bsep) and RSV (Oatps/Mrp2/Bcrp)
in rat SCH was described previously (Abe et al., 2009). Prior
studies have established that these probes are metabolically sta-
ble in rat hepatocytes (Pfeifer et al., 2013; Schwarz et al., 1975).
Briefly, day 4 SCH were washed twice with 2 ml of warm Ca2+-
containing HBSS (standard; cells + bile) or Ca2+-free HBSS
(cells) and then incubated with the same buffer for 10 min at
37◦C. Subsequently, SCH were incubated with 1.5 ml of stan-
dard HBSS containing [3H]TC (1M; 100 nCi/ml) or [3H]RSV
(1M; 100 nCi/ml) for 10 min. For acute dosing studies, PLD-
inducing drugs (AMD 50M, CHQ 10M, DES 50M, AZI
50M, or GTM 1mM) or vehicle control (0.1% DMSO) also
were added to the incubation medium along with the probe
substrates. After 10 min, SCH were washed three times with
ice-cold standard HBSS and lysed with 0.5% Triton X-100
in phosphate-buffered saline. Radioactivity in cell lysates was
quantified by liquid scintillation spectroscopy (Packard Tricarb;
PerkinElmer, Waltham, MA). Accumulation of TC and RSV
was normalized to hepatocyte total protein using a BCA protein
assay (Pierce Chemical, Rockford, IL). The biliary excretion in-
dex (BEI) and in vitro biliary clearance (CLbiliary; ml/min/kg)
were calculated using B-CLEAR R© technology (Qualyst Trans-
porter Solutions, LCC, Durham, NC) based on the following
equations:
BEI = Accumulationcells+bile − Accumulationcells
Accumulationcells+bile
(1)
CLbiliary = Accumulationcells+bile − Accumulationcells
AUCmedium0−T
(2)
where AUCmedium0−T represents the product of the incubation
time (T) and the initial TC or RSV concentration in the medium
(Abe et al., 2009; Pfeifer et al., 2013; Swift et al., 2010). CLbiliary
units were converted to ml/min/kg body weight based on pre-
viously reported values for protein content in liver tissue (200
mg/g liver weight) and liver weight (40 g/kg body weight)
(Davies and Morris, 1993).
Data analysis. The impact of chronic or acute incubation
with PLD-inducing drugs on total (cells + bile) and cellular ac-
cumulation, BEI and CLbiliary was determined using one-way
ANOVA with Dunnett’s post hoc test. A p-value <0.05 was
considered significant for all tests. All data are presented as
mean ± standard error of the mean (SEM) unless otherwise in-
dicated.
RESULTS
Rat Sandwich-Cultured Hepatocyte Toxicity
Initial pilot experiments showed that SCH incubated for 48
h with medium supplemented with 50–100M CHQ exhibited
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FIG. 1. Toxicity of AMD, CHQ, DES, AZI, and GTM (incubation for 48
h) evaluated in day 4 rat SCH measured as percent inhibition of MTT formazan
formation. SCH treated with CHQ at 100M and 0.1% DMSO (vehicle) were
used as the positive and negative controls, respectively. Data are presented as
mean ± SEM, n = 3–7 replicates measured in triplicate.
complete toxicity based on the MTT assay. Thus, SCH incu-
bated for 48 h with DMEM containing 100M CHQ or 0.1%
DMSO were selected as positive and negative (vehicle) con-
trols, respectively. SCH treated with PLD-inducing drugs ex-
hibited minimal to moderate toxicity (Fig. 1): 8–43% for AMD,
17–29% for CHQ, 2–55% for DES, 19–43% for AZI, and 26%
for GTM. Toxicity increased as the dosing concentration in-
creased for AMD, CHQ, DES, and AZI.
LysoTracker Red Localization
LysoTracker Red localization was used to assess qualitatively
the size and number of lysosomes in SCH treated with PLD-
inducing drugs. Under standard conditions, LysoTracker Red
(depicted as red/green fluorescence for contrast, Fig. 2) local-
ized in vesicles close to the canalicular membrane. Exposure
for 48 h to AMD, CHQ, DES, and AZI resulted in notably in-
creased lysosomal size and/or number relative to control (Fig.
2), suggestive of PLD. Increased background fluorescence was
observed only with CHQ treatment. Interestingly, GTM-treated
SCH did not exhibit increased lysosomal number or size.
Transmission Electron Microscopy
All major cellular organelles including the nucleus,
rough/smooth endoplasmic reticulum, Golgi apparatus, and
tight junctions between hepatocytes were visualized in each
SCH preparation. Inspection of SCH treated with 0.1% DMSO
and 1mM GTM by electron microscopy showed a large number
of mitochondria, glycogen granules, and small lysosomes;
no pathologic lysosomes and only a few lipid droplets were
observed. Inspection of SCH treated with AMD (50M), CHQ
(10M), DES (50M), and AZI (50M) showed increased
lipid droplet formation and enlarged lysosomal compartments
with electron-dense deposits and membranous structures
resembling laminar body inclusions, indicative of PLD (Fig.
3).
Accumulation and Excretion of Taurocholate and Rosuvastatin
in Rat SCH Following Acute (10-min) Exposure to
PLD-Inducing Drugs
Total and cellular accumulation, BEI, and in vitro CLbiliary of
TC and RSV were compared in SCH after acute exposure to
PLD-inducing drugs. Following a 10-min incubation of 1M
[3H]TC or [3H]RSV with vehicle control (0.1% DMSO), AMD
(50M), CHQ (10M), DES (50M), AZI (50M), or GTM
(1mM), no significant differences in total accumulation (cells
+ bile) or cellular accumulation of TC or RSV were observed.
Likewise, no statistically significant differences were observed
for BEI or in vitro CLbiliary of either TC or RSV (Fig. 4).
Accumulation and Excretion of Taurocholate and Rosuvastatin
in Rat SCH Following Chronic (48-h) Exposure to
PLD-Inducing Drugs
Accumulation of [3H]TC and [3H]RSV in cells + bile and
cells, as well as the in vitro CLbiliary, were compared between
SCH treated for 48 h with vehicle control or PLD-inducing
drugs following a 10-min incubation with 1M [3H]TC or
[3H]RSV. Total accumulation of TC (cells + bile) significantly
decreased with increasing concentrations of AMD, CHQ, DES,
and AZI (Fig. 5A). At the highest concentrations tested, TC to-
tal (cells + bile) accumulation decreased by 87.2 ± 1.8%, 71.8
± 3.2%, 73.4 ± 0.9%, and 75.3 ± 3.6% compared with control
for AMD, CHQ, DES, and AZI, respectively. TC BEI signifi-
cantly decreased at the highest tested concentrations of AMD,
DES, and AZI (Table 1). At the highest concentrations tested,
the TC CLbiliary decreased by 92.3 ± 1.4%, 76.7 ± 3.4%, 81.0 ±
1.2%, and 89.3 ± 5.1% compared with control for AMD, CHQ,
DES, and AZI, respectively. In contrast, TC cellular accumula-
tion was not affected by any treatment (Fig. 5A).
Similarly, total (cells + bile) accumulation of RSV signifi-
cantly decreased with increasing concentrations of AMD, CHQ,
DES, and AZI (Fig. 5B). At the highest concentrations tested,
RSV total (cells + bile) accumulation decreased by 89.2 ± 0.4%,
58.8 ± 2.2%, 85.2 ± 2.5%, and 77.1 ± 0.7% compared with
control for AMD, CHQ, DES, and AZI, respectively. In con-
trast to TC, cellular RSV accumulation decreased with increas-
ing concentrations of AMD, CHQ, DES, and AZI (Fig. 5B).
At the highest concentrations tested, RSV cellular accumula-
tion significantly decreased by 89.5 ± 1.8%, 68.9 ± 4.3%, 76.8
± 1.3%, and 69.4 ± 2.5% compared with control for AMD,
CHQ, DES and AZI, respectively. CLbiliary of RSV decreased
whereas BEI was unaffected by increasing concentrations of
AMD, CHQ, DES, and AZI (Table 1). At the highest concen-
trations tested, RSV CLbiliary decreased by 88.6 ± 2.8%, 50.5 ±
6.1%, 89.7 ± 2.5% and 81.4 ± 2.2%, compared with control for
AMD, CHQ, DES, and AZI, respectively. The kidney-specific
PLD-inducer, GTM, had no effect on total accumulation, cellu-
DRUG-INDUCED PHOSPHOLIPIDOSIS IN RAT SCH 103
FIG. 2. Representative images of day 4 rat SCH incubated for 30 min with 100nM LysoTracker Red following culture with PLD-inducing drugs or vehicle
control (0.1% DMSO) for 48 h; only the highest incubation concentration is shown for clarity. Upper panels: light microscopy image; middle panels: LysoTracker
Red fluorescence; lower panels: overlaid light and fluorescent images filtered to appear blue and green, respectively, for contrast (inset in upper right is enlarged
image). Scale bar in upper left corner of each image represents 20 m.
FIG. 3. Representative electron micrographs of day 4 rat SCH after 48
h culture with PLD-inducing drugs or vehicle control (0.1% DMSO). Arrows
indicate normal or enlarged laminar body-containing lysosomes. Scale bar rep-
resents 0.5 m for all PLD-inducing drugs except control and gentamicin, for
which the scale bar represents 2 and 1 m, respectively.
lar accumulation, BEI or in vitro CLbiliary of TC or RSV (Fig. 5,
Table 1).
DISCUSSION
The primary goal of this study was to determine whether rat
SCH could be used to detect hepatic drug-induced PLD. In ad-
dition, studies were designed to assess whether lysosomal dys-
function altered vectorial transport of two metabolically stable
probe compounds (Pfeifer et al., 2013; Schwarz et al., 1975), TC
and RSV. Five structurally different prototypic PLD-inducing
drugs with distinct mechanisms were selected: AMD, CHQ,
DES, AZI, and GTM. All of these drugs are known to cause
hepatic PLD, with the exception of GTM, which induces PLD in
kidney at human-relevant physiologic concentrations. Maximal
plasma concentrations (Cmax) following standard doses of AMD
(∼4.3M), CHQ (∼3.7M), DES (∼1.9M), AZI (∼1.1M)
and GTM (∼12M) were considered in selection of the low-
est concentration of PLD-inducing drugs (1M) for investiga-
tion in the SCH system (Micromedex, 2014). Concentrations
that approximated 10- and 50-fold above the Cmax values also
were examined because these drugs accumulate in hepatocytes.
The high concentration of GTM was selected as a negative con-
trol to demonstrate that hepatic PLD would not be detected,
and no changes in transport of anionic substrates would be ob-
served. Experiments with the well-established lysosomal imag-
ing probe, LysoTracker Red, demonstrated that a 48-h exposure
of rat SCH to each of the four hepatic PLD inducers resulted in
a qualitative increase in the number and/or size of lysosomal
compartments, indicative of PLD (Fig. 2). The increased back-
ground noted in SCH treated with CHQ likely was due to an in-
crease in lysosomal pH associated with CHQ’s distinct mecha-
nism of action (inhibition of H+-ATPase) (Goldman et al., 2009;
Ndolo et al., 2010). Nonetheless, distinct and enlarged lyso-
somal compartments could be visualized in SCH treated with
CHQ. As anticipated, GTM had no effect on either lysosomal
number or size (Fig. 2).
Transmission electron microscopy of rat SCH exposed for 48
h to PLD-inducing drugs enabled visualization of all major or-
ganelles; enlarged lysosomal compartments with laminar fig-
ures diagnostic of PLD were observed in SCH treated with all
PLD-inducing drugs except for GTM, which had no effect (Fig.
3). These results suggest that LysoTracker Red may be a useful
tool to screen novel drug candidates in SCH for hepatic PLD
potential (Kazmi et al., 2013; Figs. 2 and 3). Transmission elec-
tron microscopy also showed that both the cellular and organelle
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FIG. 4. Accumulation of TC (A) and RSV (B) in cells + bile (black bars) and cells (white bars) of day 4 rat SCH following a 10-min co-incubation (“acute
exposure”) with 1M [3H]TC or [3H]RSV in the presence of vehicle control (0.1% DMSO) or PLD-inducing drugs: AMD, CHQ, DES, AZI, and GTM. Data
represent the mean ± SEM of triplicate measurements in n = 3 hepatocyte preparations. No statistically significant differences were observed between control
versus treated for total (cell + bile) accumulation or cellular accumulation.
FIG. 5. Accumulation of TC (A) and RSV (B) in cells + bile (black bars) and cells (white bars) of day 4 rat SCH following a 10-min incubation with 1M
[3H]TC or [3H]RSV. SCH were treated for 48 h (“chronic exposure”) with vehicle control (0.1% DMSO) or PLD-inducing drugs: AMD, CHQ, DES, AZI, and
GTM. Data represent the mean ± SEM of triplicate measurements (n = 3–7 hepatocyte preparations); *p < 0.05, control versus treated.
membranes were grossly intact. Membrane disruption has been
reported in rats treated with high doses of AMD (150 mg/kg
body weight per day) for 3 weeks (Agoston et al., 2003). How-
ever, at the concentrations investigated for all PLD-inducing
drugs, there was no evidence of membrane disruption. There-
fore, the mitochondrial toxicity observed in the current work,
as measured by MTT formazan formation, does not appear to
be due to membrane disruption.
An additional benefit of the rat SCH model is the ability to as-
sess transporter-mediated vectorial flux of compounds through
the hepatocyte into bile. Two probe substrates were selected
to evaluate distinct transporters on the sinusoidal (blood side)
and canalicular (bile side) membranes of hepatocytes. TC is a
metabolically stable bile acid that is transported efficiently into
the hepatocyte via Ntcp, and excreted into bile via Bsep; RSV
is taken up by Oatps and possibly by Ntcp, and excreted into
bile by Mrp2 and Bcrp (Abe et al., 2009; Byrne et al., 2002;
Huang et al., 2006; Jemnitz et al., 2010; Kitamura et al., 2008;
Trauner and Boyer, 2003). Changes in cellular accumulation
and biliary excretion of probe compounds were examined to de-
termine potential transporter-mediated alterations due to ‘acute’
(10-min exposure with no pretreatment) and ‘chronic’ (48-h
pretreatment) administration of PLD inducers (Figs. 4 and 5).
Alterations due to PLD-inducing drugs might be attributed to
acute effects, or due to indirect effects, which would be present
only after chronic administration. Following acute administra-























































































































































































































































































































































































































































































































































































tion of each PLD-inducing drug, no significant changes were
observed in TC or RSV total accumulation, cellular accumu-
lation, BEI or CLbiliary (Fig. 4, Table 1). However, following
chronic administration, all drugs that induced PLD in SCH de-
creased CLbiliary of TC and RSV, whereas cellular accumulation
was reduced only for RSV. Reduced total accumulation, BEI
and CLbiliary of TC with no change in cellular accumulation (in
other words, reduced excretion of TC into the bile compartment)
secondary to PLD is consistent with canalicular transporter dys-
function, specifically reduced Bsep-mediated biliary excretion
in the case of TC (Annaert and Brouwer, 2005). Decreased
RSV total (cells + bile) and cellular accumulation as well as
CLbiliary, but no change in BEI, is consistent with decreased
Oatp-mediated uptake (Annaert and Brouwer, 2005). Impor-
tantly, following chronic GTM administration, PLD was not ob-
served in rat SCH, and no differences in TC or RSV disposition
were noted (Fig. 5 and Table 1). Taken together, results from
the acute- and chronic-exposure experiments indicated that PLD
leads to functional changes in hepatic Oatp- and Bsep-mediated
uptake and excretion, respectively. Results also suggest that
Ntcp function is maintained and that RSV biliary excretion, me-
diated by both Mrp2 and Bcrp, does not appear to be altered by
PLD. Lysosomal-associated alterations in the disposition and
toxicity of drugs have been reported previously. For example,
the impact of lysosomal pH-dependent entrapment on the cy-
totoxicity of chemotherapeutics with and without susceptibility
to lysosomal sequestration was examined (Ndolo et al., 2010).
When pH-dependent lysosomal sequestration was inhibited by
CHQ, cellular toxicity of the lysosomotropic chemotherapeutic
agent was enhanced, whereas no effect on toxicity was observed
for the non-lysosomotropic chemotherapeutic agent. Addition-
ally, exacerbation of the PLD phenotype with sucrose increased
the uptake and lysosomal sequestration of CHQ, which was not
observed when PLD induction was inhibited by bafilomycin
A1 (Zheng et al., 2011). Therefore, lysosomal enlargement and
sequestration appear to alter active anionic transport processes
based on the present results, as well as the intracellular disposi-
tion of lysosomotropic drugs (Ndolo et al. 2010; Zheng et al.,
2011).
Some limitations are associated with this work. First, com-
pared with many published studies using immortalized cell lines
to screen PLD potential, fewer drugs have been studied in rat
SCH. Although this model is lower throughput than typical im-
mortalized cell line screens, development of hepatic-specific
PLD with drugs that exhibited a range of hepatic induction po-
tency was demonstrated (AMD and CHQ are strong inducers
whereas DES and AZI are weaker hepatic PLD inducers). Ad-
ditionally, the PLD-inducing drugs investigated in this study
affect different organ systems in vivo and have diverse pos-
tulated induction mechanisms in vivo (i.e,. inhibition of phos-
pholipid metabolism with AMD, inhibition of H+-ATPase with
CHQ). The present data indicate that rat SCH are both a sen-
sitive and specific model for identification of drugs that cause
hepatic PLD. All drugs tested, including GTM, caused mild to
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moderate toxicity based on the MTT assay (Fig. 1). Although
drug-induced PLD has not been associated directly with cellular
toxicity, the altered anionic transport observed may be related
to toxicity. Interestingly, moderate toxicity was observed with
GTM although no PLD or change in TC or RSV transport was
apparent. This supports the hypothesis that altered TC and RSV
transport secondary to PLD are not likely caused solely by the
mild to moderate toxicity observed. Additionally, preliminary
data indicate that streptomycin, an aminoglycoside included in
the feeding medium that is structurally similar to GTM, did not
induce PLD at the low concentrations utilized (172nM).
Drug-induced PLD leads to impaired phospholipid storage,
metabolism, and excretion (Reasor et al., 1989). Several model
systems have been evaluated to identify PLD-inducing drugs as
early as possible during drug development. As such, PLD po-
tential often is identified during early preclinical development
and is handled on a case-by-case basis depending on the severity
and target organ(s) affected (Chatman et al., 2009). This case-
based assessment poses challenges due to a limited understand-
ing of the (presumed) association between PLD and organ toxi-
city. Consequently, increasing attention has been placed on de-
veloping sensitive and specific models to predict drug-induced
PLD, thereby avoiding late-stage failures due to unanticipated
toxicities. A report by leading investigators encourages selec-
tion of lead drug candidates based on in silico and/or in vitro
screening for PLD potential (Chatman et al., 2009). Multiple in
silico quantitative structure-activity relationship (QSAR) and in
vitro non-cell-based and cell-based models have been developed
(Kazmi et al., 2013; LeCureux et al., 2011; Pelletier et al., 2007;
Ploemen et al., 2004; Shahane et al., 2013; Vitovic et al., 2008;
Zhou et al., 2011). These screening methods have identified pri-
marily CADs as causal agents, with a few notable exceptions
(i.e., GTM). Although invaluable for initial risk-benefit analy-
ses, these models have limitations. In vitro (and by inference
in silico) models that lack metabolic and transport processes
may underestimate PLD potential, as evidenced by the obser-
vation that isolated, metabolically active murine macrophages
exhibited greater sensitivity and specificity to predict PLD in
vivo than immortalized cell lines (LeCureux et al., 2011). Addi-
tionally, organ-specific transporters and metabolizing enzymes
are germane to assess PLD potential in vitro as well as facili-
tate accurate in vivo extrapolation to target organs. SCH are a
well-established system expressing hepatic-relevant metaboliz-
ing enzymes and transport proteins, which may aid in increas-
ing assay sensitivity to identify drugs that require metabolism
or transport to induce hepatic PLD (Swift et al., 2010).
In conclusion, rat SCH are a viable system to evaluate drug-
induced hepatic PLD. Initial screening with LysoTracker Red
localization would increase throughput. PLD screening should
be evaluated in a metabolically capable cell-based model such
as SCH, which provide the additional benefit that transport pro-
cesses can be evaluated concurrently. The present data reveal for
the first time that drug-induced hepatic lysosomal dysfunction
may be associated with altered Oatp- and Bsep-mediated an-
ionic transport. Clearly, PLD-inducing drugs may exhibit many
toxicologic endpoints that require further preclinical evaluation.
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